The Institute for Clinical and Economic Review (ICER) released its first report on drug price increases unsupported by new clinical evidence.
According to a press release, ICER used data from SSR Health Inc. to look evaluate price increases on the top 100 grossing drugs in the U.S.
“Following consideration of input from manufacturers and a systematic review of evidence available in published studies, ICER determined that seven of the nine drugs had evidence that was not adequate to support a claim of additional clinical benefit,” the press release states.
The National Pharmaceutical Council (NPC) released a statement that disputes ICER’s Unsupported Price Increase report. To read NPC’s response, click here.
To read ICER’s full report, click here.